New exec team, new money and a big syndicate — ORIC heads to PhII
Bay Area biotech ORIC Pharmaceuticals has scored a fresh $55 million raise to back its push into Phase II studies for its glucocorticoid receptor antagonist ORIC-101. The money comes just 18 months after a $50 million C round.
The cash is being used to field a slate of new studies for solid tumors, with combos using Abraxane and an androgen receptor modulator for prostate cancer. And there’s an oral small molecule inhibitor of CD73 to steer into Phase I as well.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
